Posts Archive

Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and...

IFM 2017-04 - CARRISMM NCT04144387: Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New...

DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...

NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Dara-KPd This research study is studying the...

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients Study to Assess for Measurable Residual Disease (MRD)...

NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma Low-Dose Radiotherapy in...

DREAMM 9 - Transplant Ineligible - Newly Diagnosed Multiple Myeloma Part 1: Dose escalation and cohort expansion Part 2: Dose selection...

DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...

NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in...

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)...

CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy MGUS Rifaximin in Patients With Monoclonal Gammopathy This trial...

NCT04155749: Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Master Protocol for the Phase 1 Study...

DREAMM 5 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With...

LENAZART Study LEN-AZA-RT NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma...

NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM Ixazomib + Pomalidomide + Dexamethasone In MM This is a Phase I/II...

PROMISE NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population The PROMISE Study aims to...

(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab,...